Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors

esmo - Findings from the LITESPARK-011 study

AI Summary: A Phase 3 trial shows belzutifan combined with lenvatinib improves progression-free survival compared with cabozantinib in patients with advanced renal cell carcinoma who progressed on PD‑1/PD‑L1 inhibitors. The result offers a new sequenced treatment option and shifts the landscape for post–checkpoint inhibitor RCC management.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials

Local Renal Cell Carcinoma Recurrence: Salvage Treatment Outcomes

9 days / oncodaily

Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors

12 days / esmo

Giuseppe Caruso: Phase 3 LITESPARK-011 Shows Progression-Free Survival Benefit in Advanced RCC

15 days / oncodaily

Global atlas uncovers 55,000 RNA viruses across nearly 100 cities

15 days / medicalxpress

LITESPARK-011 Trial: Belzutifan Plus Lenvatinib vs Cabozantinib in Advanced RCC

15 days / oncodaily

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Telemedicine, Pancreatic Cancer, Obesity, Infectious Disease and look for the RSS link.

StackHealth Time Machine

More StackHealth